Clinical trials
Leukemia, Myeloid, Acute trials in Poland
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
75 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 1 |
| 2005 | 2 |
| 2008 | 1 |
| 2009 | 2 |
| 2010 | 3 |
| 2011 | 3 |
| 2012 | 1 |
| 2013 | 4 |
| 2014 | 4 |
| 2015 | 4 |
| 2016 | 4 |
| 2017 | 9 |
| 2018 | 5 |
| 2019 | 6 |
| 2020 | 4 |
| 2021 | 7 |
| 2022 | 4 |
| 2023 | 1 |
| 2024 | 5 |
| 2025 | 5 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 39 |
| Recruiting | 11 |
| Terminated | 11 |
| Active, not recruiting | 8 |
| Enrolling by invitation | 3 |
| Unknown status | 2 |
| Suspended | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Novartis Pharmaceuticals | 6 |
| Astellas Pharma Global Development, Inc. | 4 |
| Daiichi Sankyo | 4 |
| Ryvu Therapeutics SA | 4 |
| Taiho Oncology, Inc. | 4 |
| Celgene | 3 |
| Janssen Research & Development, LLC | 3 |
| Moleculin Biotech, Inc. | 3 |
| Pfizer | 3 |
| AbbVie | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Leukemia, Myeloid, Acute | 75 |
| Myelodysplastic Syndromes | 17 |
| Leukemia | 13 |
| Recurrence | 8 |
| Leukemia, Myelomonocytic, Chronic | 6 |
| Neoplasms | 6 |
| Hematologic Diseases | 4 |
| Hematologic Neoplasms | 3 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 3 |
| Lymphoma, Non-Hodgkin | 3 |
Trials
Showing 26 to 50 of 75. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.